Metabolomics During Testosterone Therapy

ClinicalTrials.gov ID: NCT01963390

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01963390. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Testosterone Therapy and Its Effects on Metabolic Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

One promising but understudied area in the field of testosterone (T) therapy is its effect on metabolism and the development of type II diabetes. Metabolomics is a powerful research tool that can detect very early signs of metabolic derangement that may lead to metabolic disease. In this observational study, investigators aim to apply metabolomics in order to better understand how T therapy influences metabolism. In a clinical population of outpatient men with T deficiency investigators will perform comprehensive clinical evaluations and also obtain blood for metabolomics. This will be done once prior to T therapy and again after 4-6 months of T therapy. Investigators hypothesize that they can detect metabolic derangements in men with T deficiency and that these derangements will improve with T therapy.

Study identification

NCT ID: NCT01963390
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Men's Health Boston; Other
Enrollment: 60 participants

Conditions and interventions

Conditions

Testosterone Deficiency

Interventions

Testosterone Therapy Drug

Drug

Eligibility (public fields only)

Age range: 20 Years to 90 Years
Sex: Male
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2012 (Type not available)
Primary completion: Jun 2017 (Actual)
Completion: Dec 2017 (Actual)
Last update posted: Apr 19, 2018

2012 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Men's Health Boston	Chestnut Hill	Massachusetts	02467	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01963390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2018 · Synced Nov 12, 2026